Results 101 to 110 of about 225,025 (354)

Long-lasting cross-protection against influenza A by neuraminidase and M2e-based immunization strategies [PDF]

, 2016
There is mounting evidence that in the absence of neutralizing antibodies cross-reactive T cells provide protection against pandemic influenza viruses. Here, we compared protection and CD8+ T cell responses following challenge with H1N1 2009 pandemic and
Callewaert, Nico, Fiers, Walter, Saelens, Xavier, Schepens, Bert, Schotsaert, Michael, Smet, Anouk, Stegalkina, Svetlana, Vanderschaeghe, Dieter, Vogel, Thorsten U, Ysenbaert, Tine   +9 more
core   +2 more sources

Novel Platforms for the Development of a Universal Influenza Vaccine

Frontiers in Immunology, 2018
Despite advancements in immunotherapeutic approaches, influenza continues to cause severe illness, particularly among immunocompromised individuals, young children, and elderly adults.
Arun Kumar, Arun Kumar, Trine Sundebo Meldgaard, Trine Sundebo Meldgaard, Sylvie Bertholet, Sylvie Bertholet   +5 more
doaj   +1 more source

A Modular Vaccine Platform Against SARS‐CoV‐2 Based on Self‐Assembled Protein Nanoparticles

Advanced Science, EarlyView.
A modular BP26 nanoparticle vaccine platform incorporating the SpyTag/SpyCatcher system enables high‐density, repetitive antigen display with post‐expression flexibility. Conjugation of the SARS‐CoV‐2 RBD to BP26 nanoparticles elicits strong humoral immunity and confers protection against viral challenge in vivo.
Seojung Lee, Yejin Jang, Yujin Kim, Yumi Shin, Ji‐Joon Song, Meehyein Kim, Sangyong Jon   +6 more
wiley   +1 more source

DNA Nanostructure‐Templated Multivalency Enables Broad‐Spectrum Virus Inhibition

Advanced Science, EarlyView.
A honeycomb‐shaped DNA nanostructure is introduced that organizes nanobodies or aptamers into trimeric clusters mirroring the native hemagglutinin arrangement on influenza viruses. This geometry‐matched multivalency enhances binding avidity by up to 1000‐fold, resulting in robust, broad‐spectrum viral neutralization and a 30–55% improvement in host ...
Saurabh Umrao, Abhisek Dwivedy, Dhanush Gandavadi, Chi Chen, Lifeng Zhou, Jinwei Duan, Vineetha Mareddy, Ying Fang, Xing Wang   +8 more
wiley   +1 more source

Your Best Shot at Surviving the Flu Season [PDF]

, 2020
Millions of individuals become ill from the influenza virus every year. As an existing public health issue, it is important for patients to understand that the best way to combat the influenza virus is through prevention.
Liu, Isabella
core   +1 more source

Mucosal delivery of tuberculosis vaccines: a review of current approaches and challenges. [PDF]

, 2019
Introduction: Tuberculosis (TB) remains a major health threat and it is now clear that the current vaccine, BCG, is unable to arrest the global TB epidemic. A new vaccine is needed to either replace or boost BCG so that a better level of protection could
Barclay WR, Elena Stylianou, Helen McShane, Matthew J. Paul, Rajko Reljic, Resende Co T, Rodriguez A, Uranga S, Wong EA   +8 more
core   +1 more source

Pre‐Existing Th1 Immunity Outperforms Age in Predicting Antibody Responses to SARS‐CoV‐2 Inactivated Vaccines

Advanced Science, EarlyView.
Challenging the focus on age, this study finds pre‐existing T helper 1 cells are the key biomarker for predicting antibody response to SARS‐CoV‐2 inactivated vaccines. In both mice and humans, high responders exhibited elevated baseline T helper 1 cells, which correlated with robust humoral immunity, offering crucial guidance for improving vaccine ...
Chanyuan Ye, Xiaoli Zhang, Lingfeng Qiu, Jia Ji, Jueqing Gu, Hongyu Jia, Yingfeng Lu, Jiyang Chen, Zelu Meng, Jiangshan Lian, Hangping Yao, Xun Zeng, Yida Yang   +12 more
wiley   +1 more source

Characterization of potential biomarkers of reactogenicity of licensed antiviral vaccines: randomized controlled clinical trials conducted by the BIOVACSAFE consortium [PDF]

, 2019
Funding text The authors are grateful for the vital contributions of the participating study volunteers, clinicians, nurses, and laboratory technicians at the Surrey study site.
Bodinham, C., Bottazzi, B., DelGiudice, G., Denoel, P., Greenwood, A., Jonsdottir, I., Kaufmann, S., Kester, K., Leroux-Roels, G., Lewis, D., Linley, C., Maertzdorf, J., Mantovani, A., Mollenkopf, H., Pizzoferro, K., van den Berg, R., Weiner, J.   +16 more
core   +1 more source

Antiemesis Corticosteroids Potentiate Checkpoint Blockade Efficacy by Normalizing the Immune Microenvironment in Metastatic Murine Breast Cancer

Advanced Science, EarlyView.
Corticosteroids improve the efficacy of immune checkpoint blockade therapy in metastatic murine breast cancer. By normalizing the tumor immune microenvironment, corticosteroids reduce immunosuppressive signals, restore T‐cell function, and promote antitumor immune responses, resulting in enhanced tumor control.
John D. Martin, Koji Nagaoka, Myrofora Panagi, Akihiro Hosoi, Fotios Mpkeris, Pengwen Chen, Thahomina T. Khan, Margaret R. Martin, Changbo Sun, Chrysovalantis Voutouri, Maria Louca, Panagiotis Papageorgis, Akira Sumiyoshi, Nobuhiro Nitta, Kazuyoshi Takeda, Ichio Aoki, Kazunori Kataoka, Triantafyllos Stylianopoulos, Kazuhiro Kakimi, Horacio Cabral   +19 more
wiley   +1 more source

Programmable Antigen‐Specific Immunity via Self‐Adjuvanting Nanovaccines Co‐Delivering Immune Modulators

Angewandte Chemie, EarlyView.
The self‐adjuvanting vaccine—comprising a covalent conjugate of antigen and adjuvant—was formulated into cationic lipid nanoparticles smaller than 100 nm to facilitate uptake by immune cells, with supplemental adjuvants incorporated to modulate immune responses.
Keita Ito, Yoshiyuki Manabe, Shino Ohshima, Masatoshi Maeki, Manabu Tokeshi, Hiroshi Inaba, Kazunori Matsuura, Kazuya Kabayama, Yoshie Kametani, Koichi Fukase   +9 more
wiley   +2 more sources